Bio-Rad Laboratories, Inc. (USD) Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Bio-Rad Laboratories, Inc. (USD) Active

1000 Alfred Nobel Drive, Hercules, CA, US, 94547

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

BIO's stock peer is ALGN (Align Technology, Inc.)

BIO's stock peer is ATR (AptarGroup, Inc.)

BIO's stock peer is CRL (Charles River Laboratories International, Inc.)

BIO's stock peer is GMED (Globus Medical, Inc.)

BIO's stock peer is GRFS (Grifols, S.A.)

BIO's stock peer is HQY (HealthEquity, Inc.)

BIO's stock peer is HSIC (Henry Schein, Inc.)

BIO's stock peer is MASI (Masimo Corporation)

BIO's stock peer is PEN (Penumbra, Inc.)

Healthcare Medical - Devices

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

80%

Dcf Rating

60%

Return On Equity

80%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention taking place this week in San Diego, California.

2026-06-22 16:03:00

CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026

"Not Just Reducing, But Designing Better Taste" CHICAGO and DOWNERS GROVE, Ill., June 22, 2026 /PRNewswire/ -- CJ BIO will participate in IFT FIRST 2026, taking place July 13–15, 2026, at McCormick Place in Chicago.

2026-06-22 11:39:00

Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.

2026-06-22 08:30:00

New Mexico Bioscience Delegation Showcases Innovation and Industry Growth at BIO International Convention 2026

Albuquerque, NM, June 18, 2026 (GLOBE NEWSWIRE) -- A delegation of economic development, research, healthcare, and industry leaders will represent New Mexico's growing bioscience sector at the BIO International Convention, taking place June 22–25, 2026, in San Diego, California. Led by the Albuquerque Regional Economic Alliance (AREA), the delegation will promote New Mexico's bioscience industry, highlight the state's innovation ecosystem, and connect with companies, investors, and industry leaders from around the globe.

2026-06-18 14:45:00

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health

2026-06-18 09:20:00

Fujifilm Life Sciences at BIO 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millions of patients worldwide still lack access to vital medicines. At BIO International Convention 2026, taking place June 22-25 at the San Diego Convention Center, Fujifilm's Life Sciences group will showcase how its integrated global ecosystem is helping biopharmaceutical innovators accelerate the path from discovery to delivery. The company's expanding life sciences portfolio supports therapeutics from discovery to commercialization, serving as “Partners.

2026-06-18 09:00:00

Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026

Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the launch of its artificial intelligence ("AI") powered good manufacturing practices ("GMP") manufacturing services platform (the "Platform") at the 2026 BIO International Convention in San Diego, California.

2026-06-18 08:00:00

BIO-key's Fireside Chat at Maxim Group Defense Tech Conf. to Webcast Thur.

Biometric authentication provider BIO-key's (BKYI) CEO will participate in a webcast fireside chat at Maxim Group's Defense Tech Conf. 6-25 at 4pm, track 2

2026-06-18 07:59:00

BioHarvest Sciences to Present at the 2026 BIO International Convention

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.

2026-06-18 07:30:00

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California.

2026-06-17 07:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions